Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva is a diversified healthcare company with a strong portfolio of royalty assets, a growing commercial platform focused on critical care and infectious disease, and strategic investments in various healthcare assets. The company's strong financial position, with a solid cash position and future royalty rights, allows for further inorganic growth opportunities, while its current internal marketed products show impressive revenue growth. Additionally, its strategic equity investments, including majority stakes in innovative companies such as Armata and Syndeio, have the potential to drive significant upside for shareholders in the future.

Bears say

Innoviva is heavily reliant on acquisitions for growth, and while management has expressed interest in additional assets, competition in the infectious disease/critical care medicine space is limited, allowing the company to purchase assets at a discount rather than a competitive bid. However, their recent strategic investment in Armata could possibly provide a potential avenue for growth as their antibiotic platform has shown promise in treating antibiotic-resistant bacteria. It remains to be seen how successful this investment will be and the potential impact on Innoviva's overall financials.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.